Fennec Pharmaceuticals (FENC) investor relations material

Product overview and market position

• PEDMARK is the first and only FDA-approved therapy for preventing cisplatin-induced hearing loss, with approval received in September 2022 and NCCN Category 2A endorsement for ages 15–39.

• Global partnerships established in Europe, Australia, New Zealand, Middle East, and Turkey, with ongoing efforts to secure a partner in Japan.

• Robust IP portfolio with patents extending to 2039 and 10 years of exclusivity in Europe under PUMA.

• PEDMARK addresses a significant unmet need, as up to 90% of cisplatin-treated patients experience hearing loss.

• The product is positioned as a prophylactic solution, administered six hours after each cisplatin dose.

Commercial strategy and execution

• Leadership overhaul and commercial team expansion from 10 to 24 territories to target the larger AYA market.

• Focused on building brand awareness, KOL engagement, and advocacy, with over 90% reimbursement rates achieved.

• Commercial and medical infrastructure doubled FTEs from 30 to 60, aligning with market expansion.

• Fennec HEARS program provides medical and logistical support, including home health partnerships.

• Successful market penetration in both pediatric and AYA segments, with tailored sales approaches for each.

Financial performance and outlook

• Clean balance sheet with no debt and $40 million in cash as of June 30th.

• Achieved positive EBITDA for the first time, with $3 million reported and scalable business model.

• Revenue has more than doubled over seven consecutive quarters, driven by AYA market expansion.

• Fixed annual cash OpEx at $50 million, with incremental sales expected to flow directly to EBITDA.

• Anticipates continued growth as net sales surpass $14–15 million.